CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis
USA - NASDAQ:CORT - US2183521028 - Common Stock
76.64 USD
-1.75 (-2.23%)
We assign a fundamental rating of 7 out of 10 to CORT. CORT was compared to 191 industry peers in the Pharmaceuticals industry. CORT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CORT is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make CORT suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year CORT was profitable.
In the past year CORT had a positive cash flow from operations.
CORT had positive earnings in each of the past 5 years.
In the past 5 years CORT always reported a positive cash flow from operatings.
1.2 Ratios
CORT's Return On Assets of 12.88% is amongst the best of the industry. CORT outperforms 93.19% of its industry peers.
Looking at the Return On Equity, with a value of 16.79%, CORT belongs to the top of the industry, outperforming 90.05% of the companies in the same industry.
CORT has a Return On Invested Capital of 8.69%. This is amongst the best in the industry. CORT outperforms 86.91% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CORT is above the industry average of 15.35%.
The 3 year average ROIC (17.94%) for CORT is well above the current ROIC(8.69%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.88% | ||
| ROE | 16.79% | ||
| ROIC | 8.69% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
1.3 Margins
CORT has a better Profit Margin (14.32%) than 87.96% of its industry peers.
CORT's Profit Margin has declined in the last couple of years.
The Operating Margin of CORT (8.85%) is better than 81.68% of its industry peers.
CORT's Operating Margin has declined in the last couple of years.
The Gross Margin of CORT (98.19%) is better than 97.91% of its industry peers.
In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.85% | ||
| PM (TTM) | 14.32% | ||
| GM | 98.19% |
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CORT is creating value.
Compared to 1 year ago, CORT has more shares outstanding
CORT has less shares outstanding than it did 5 years ago.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CORT has an Altman-Z score of 28.60. This indicates that CORT is financially healthy and has little risk of bankruptcy at the moment.
CORT has a Altman-Z score of 28.60. This is amongst the best in the industry. CORT outperforms 93.72% of its industry peers.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 28.6 |
ROIC/WACC0.98
WACC8.91%
2.3 Liquidity
A Current Ratio of 3.14 indicates that CORT has no problem at all paying its short term obligations.
CORT's Current ratio of 3.14 is in line compared to the rest of the industry. CORT outperforms 54.45% of its industry peers.
A Quick Ratio of 3.07 indicates that CORT has no problem at all paying its short term obligations.
CORT's Quick ratio of 3.07 is in line compared to the rest of the industry. CORT outperforms 56.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.07 |
3. Growth
3.1 Past
The earnings per share for CORT have decreased strongly by -30.16% in the last year.
The Earnings Per Share has been growing by 9.71% on average over the past years. This is quite good.
The Revenue has grown by 17.92% in the past year. This is quite good.
Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 17.11% on average per year.
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
3.2 Future
Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 54.86% on average per year.
Based on estimates for the next years, CORT will show a very strong growth in Revenue. The Revenue will grow by 30.93% on average per year.
EPS Next Y-17.95%
EPS Next 2Y27.38%
EPS Next 3Y64.99%
EPS Next 5Y54.86%
Revenue Next Year23.1%
Revenue Next 2Y28.9%
Revenue Next 3Y31.29%
Revenue Next 5Y30.94%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 87.09, CORT can be considered very expensive at the moment.
76.96% of the companies in the same industry are more expensive than CORT, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CORT to the average of the S&P500 Index (26.34), we can say CORT is valued expensively.
Based on the Price/Forward Earnings ratio of 38.09, the valuation of CORT can be described as expensive.
Based on the Price/Forward Earnings ratio, CORT is valued a bit cheaper than the industry average as 70.68% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of CORT to the average of the S&P500 Index (34.43), we can say CORT is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 87.09 | ||
| Fwd PE | 38.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CORT is valued a bit cheaper than the industry average as 76.96% of the companies are valued more expensively.
CORT's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CORT is cheaper than 78.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 49.68 | ||
| EV/EBITDA | 113.59 |
4.3 Compensation for Growth
The excellent profitability rating of CORT may justify a higher PE ratio.
CORT's earnings are expected to grow with 64.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)8.96
EPS Next 2Y27.38%
EPS Next 3Y64.99%
5. Dividend
5.1 Amount
CORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CORT (11/13/2025, 1:11:33 PM)
76.64
-1.75 (-2.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners76.03%
Inst Owner Change1.44%
Ins Owners6.58%
Ins Owner Change-0.01%
Market Cap8.08B
Revenue(TTM)741.17M
Net Income(TTM)106.11M
Analysts82
Price Target137.93 (79.97%)
Short Float %11%
Short Ratio11.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.91%
Min EPS beat(2)16.19%
Max EPS beat(2)51.63%
EPS beat(4)3
Avg EPS beat(4)11.15%
Min EPS beat(4)-40.2%
Max EPS beat(4)51.63%
EPS beat(8)7
Avg EPS beat(8)17.67%
EPS beat(12)9
Avg EPS beat(12)13.54%
EPS beat(16)12
Avg EPS beat(16)12.14%
Revenue beat(2)0
Avg Revenue beat(2)-5.62%
Min Revenue beat(2)-6.85%
Max Revenue beat(2)-4.4%
Revenue beat(4)0
Avg Revenue beat(4)-8.72%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)-4.4%
Revenue beat(8)4
Avg Revenue beat(8)-2.84%
Revenue beat(12)6
Avg Revenue beat(12)-1.78%
Revenue beat(16)7
Avg Revenue beat(16)-2.44%
PT rev (1m)-0.02%
PT rev (3m)0.54%
EPS NQ rev (1m)-19.4%
EPS NQ rev (3m)-66.67%
EPS NY rev (1m)-7.64%
EPS NY rev (3m)-27.59%
Revenue NQ rev (1m)-2.34%
Revenue NQ rev (3m)-11.72%
Revenue NY rev (1m)-1.47%
Revenue NY rev (3m)-5.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 87.09 | ||
| Fwd PE | 38.09 | ||
| P/S | 10.9 | ||
| P/FCF | 49.68 | ||
| P/OCF | 49.59 | ||
| P/B | 12.78 | ||
| P/tB | 12.78 | ||
| EV/EBITDA | 113.59 |
EPS(TTM)0.88
EY1.15%
EPS(NY)2.01
Fwd EY2.63%
FCF(TTM)1.54
FCFY2.01%
OCF(TTM)1.55
OCFY2.02%
SpS7.03
BVpS6
TBVpS6
PEG (NY)N/A
PEG (5Y)8.96
Graham Number10.9
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.88% | ||
| ROE | 16.79% | ||
| ROCE | 10.07% | ||
| ROIC | 8.69% | ||
| ROICexc | 24.92% | ||
| ROICexgc | 24.92% | ||
| OM | 8.85% | ||
| PM (TTM) | 14.32% | ||
| GM | 98.19% | ||
| FCFM | 21.93% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexgc growth 3Y-18.86%
ROICexgc growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 36.2% | ||
| Cap/Sales | 0.04% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 245.43% | ||
| Profit Quality | 153.21% | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.07 | ||
| Altman-Z | 28.6 |
F-Score6
WACC8.91%
ROIC/WACC0.98
Cap/Depr(3y)112.18%
Cap/Depr(5y)124.4%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
EPS Next Y-17.95%
EPS Next 2Y27.38%
EPS Next 3Y64.99%
EPS Next 5Y54.86%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
Revenue Next Year23.1%
Revenue Next 2Y28.9%
Revenue Next 3Y31.29%
Revenue Next 5Y30.94%
EBIT growth 1Y-54.26%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year-34.64%
EBIT Next 3Y41.42%
EBIT Next 5Y19.15%
FCF growth 1Y5.22%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y5.34%
OCF growth 3Y5.66%
OCF growth 5Y7.79%
CORCEPT THERAPEUTICS INC / CORT FAQ
What is the ChartMill fundamental rating of CORCEPT THERAPEUTICS INC (CORT) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CORT.
What is the valuation status for CORT stock?
ChartMill assigns a valuation rating of 5 / 10 to CORCEPT THERAPEUTICS INC (CORT). This can be considered as Fairly Valued.
Can you provide the profitability details for CORCEPT THERAPEUTICS INC?
CORCEPT THERAPEUTICS INC (CORT) has a profitability rating of 8 / 10.
What is the financial health of CORCEPT THERAPEUTICS INC (CORT) stock?
The financial health rating of CORCEPT THERAPEUTICS INC (CORT) is 8 / 10.